Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that v::NTRK2 status confers therapeutic sensitivity to Larotrectinib in patients with Any solid tumor.
Health Canada approved larotrectinib for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.
This statement is based on a regulatory approval from the Health Canada:
VITRAKVI (larotrectinib) is indicated for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2025-04-30 | Van Allen lab | The FDA provided regular approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. |
| 2024-10-30 | Van Allen lab | Initial access of FDA approvals |